TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03247322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication therapy using mHealth application
Description: This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
Study: NCT03440138

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity

Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity
Study: NCT03785314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization with different posture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization with different posture
Study: NCT02210507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofortified cassava gari
Description: Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White cassava gari
Description: Non-biofortified (white) cassava and a retinyl palmitate reference dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White cassava gari + red palm oil
Description: Non-biofortified (white) cassava gari containing red palm oil.
Study: NCT04399889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.
Description: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University or University of Miami.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.
Description: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University or University of Miami.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be comprised of 40-80 mL of Plasmalyte-A + 1% Human Serum Albumin (HAS) prepared in an identical container to the one used for cell administration. The placebo product will undergo the same process of sterility testing including release inspection, transport and product custodian.
Study: NCT05644678

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed appliances
Description: Metal brackets with a straight-wire prescription will be used. Patients will be treated conventionally.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: Patients will be treated in conjunction with a surgical intervention using metal brackets with a straight-wire prescription. Corticotomy (alveolar perforation and piezocision) will induce acceleration in canine traction movement during the orthodontic treatment in only one group.
Study: NCT03886584

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring source test
Description: Internal- and external-monitoring correct responses and inversions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring source test
Description: Internal- and external-monitoring correct responses and inversions
Study: NCT01537835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial Scrubs
Description: Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial Scrubs
Description: Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
Study: NCT00926341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Tab. Pioglitazone-30 mg/day, oral, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Tab. Telmisartan- 40 mg/day, oral, 24 weeks
Study: NCT02163681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Helium-3 MRI of the chest
Description: hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
Study: NCT02072941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE Intervention
Description: At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
Study: NCT01996150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleach bath (sodium hypochlorite)
Description: Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
Study: NCT01254656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lersivirine
Description: Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lersivirine
Description: Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lersivirine
Description: Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lersivirine
Description: Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etravirine
Description: Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
Study: NCT00412789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Study: NCT03821246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Given Orally
Study: NCT02119078

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Care of Elders focused geriatric care
Description: Patients admitted to the ACE Service will receive standard care as well as additional use of geriatric-specific order sets and protocols and oversight of care by a geriatric-trained Advanced Practice Provider (APP).
Study: NCT01067417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Taken orally 2x200mg capsules once daily for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken orally 2x200mg capsules once daily for 48 weeks
Study: NCT02196857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
Study: NCT02589509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct-attention training using web-based BrainHQ
Description: BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct-attention training using web-based BrainHQ
Description: BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Description: A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Description: A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
Study: NCT02170857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: This material will be used in conjunction with the ordinary surgical procedure
Study: NCT04687111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Sacubitril-Valsartan is an Angiotensin Receptor blocker and Neprilysin Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan is an Angiotensin Receptor Blocker
Study: NCT01005901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide
Description: Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation capsules were provided for use via a SDDPI
Study: NCT03556969

Intervention type: OTHER
Intervention: Observation
Description: no intervention
Study: NCT03929263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback
Description: Participants will attempt to regulate own and/or their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
Study: NCT03549598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE PET/CT
Description: 5.4 mCi of 68Ga-DOTATATE will be administered by intravenous route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18FDG PET/CT scan
Description: This scan will be performed as part of the planned clinical care for the patient. Dose of 18FDG will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13NH3 PET/CT scan
Description: This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
Study: NCT00533221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatotropin
Description: 0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
Study: NCT02750696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days
Description: Patients in this group received opioid/ non-opioid analgesic combination.
Study: NCT00068003

Intervention type: DRUG
Intervention: Anti-CD19 CAR PBL
Study: NCT02750696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days
Description: Patients in this group received opioid/ non-opioid analgesic combination.
Study: NCT00618826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
Study: NCT01690195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: See arm description
Study: NCT03079167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT01025102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naropin 0.1% cum sufentanil
Description: 20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
Study: NCT06265909

Intervention type: DEVICE
Intervention: AmDTx
Description: AmDTx (Mobio Interactive Pte Ltd, Singapore), is an advanced mobile health platform equipped with computer vision and AI to objectively quantify psychological stress and benchmarked ecological momentary assessments to subjectively measure stress, valence, and arousal. Asynchronous and on-demand psychotherapy available as audio files within AmDTx has been clinically validated across the mental illness severity spectrum. Psychotherapy within AmDTx primarily leverages meditation/mindfulness techniques to enhance relaxation, build stress resilience, improve focus and decision making, and influence behaviour and affect bias.
Study: NCT02811991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol injection
Description: 325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline injection
Description: 32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morhpine PCA
Description: Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose\<25mg/4h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morhpine PCA
Description: Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose\<25mg/4h.
Study: NCT04642482

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic (Rillus)
Description: Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
Study: NCT00825838

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chronic consumption of chili pepper extract
Description: 6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chronic consumption of matching placebo
Description: 0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
Study: NCT04039659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative-pressure wound therapy (PICO)
Description: After the selection of patients and the signing of the consent, patients will be randomized and the device will be placed to those who belong to the PICO group in the operating room.
Study: NCT01440985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine Gum 2 mg, Lot number GD922A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine gum 4 mg, Lot number GC962A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine Microtab 2 mg, Lot number GB196G
Study: NCT00667303

Intervention type: OTHER
Intervention: Nasopharyngeal Washes
Description: A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.

Intervention type: OTHER
Intervention: Fluorescent antibody detection
Description: For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.

Intervention type: OTHER
Intervention: Respiratory viral culture
Description: Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
Study: NCT01384747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: 60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
Study: NCT04021498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
Study: NCT03887585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Achilles tendon lengthening
Description: Achilles tendon lengthening by triple hemisection for Achilles tendon contracture
Study: NCT04724785

Intervention type: OTHER
Intervention: only monitoring
Description: monitoring the viraemia only

Intervention type: OTHER
Intervention: monitoring and regimen change if necessary
Description: if those patients agree, the regimen will be changed.

Intervention type: DRUG
Intervention: regimen change
Description: Based on ongoing one, regimen will be changed . The principle for adjusting anti-viral regimen is as follows: 1. The patients were treated with second-line drugs: changing ADV to ETV/TAF/TDF , changing LAM to TAF/TDF and changing LdT to TAF/TDF; 2. The patients were treated with ETV: adding or switching to TAF/TDF;3. TAF or ETV is recommended for patients with one or more TDF risk factors, such as \> 40 years old, patients with abnormal bone/kidney related indicators or patients with high risk of bone/kidney injuries.【ADV=adefovir dipivoxil, LAM=lamivudine, and LdT=telbivudine , TAF =Tenofovir alafenamide Fumarate, ETV=Entecavir and TDF=Tenofovir disoproxil fumarate 】